Oxford Ovarian Cancer Predict Chemotherapy Response 01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

35 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-11-30

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to understand why there are differences between individuals in the way they respond to paclitaxel chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacogenomics of Paclitaxel in Ovarian Cancer

NCT00415207

Ovarian Neoplasms Fallopian Tube Neoplasms

COMPLETED

Pharmacogenomics of Paclitaxel in Ovarian Cancer

NCT00415181

Ovarian Neoplasms Fallopian Tube Neoplasms

COMPLETED

Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

NCT00005046

Ovarian Cancer Primary Peritoneal Cavity Cancer

COMPLETED PHASE1

Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer

NCT00002928

Ovarian Cancer

COMPLETED PHASE2

Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas

NCT00750386

Ovarian Cancer

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

While paclitaxel is very effective in killing cancer cells in a proportion of patients, some patients don't respond to this treatment. As with any chemotherapy, paclitaxel is associated with unpleasant side effects. We are doing this study to try and understand what is happening in cancer cells in different individuals after paclitaxel treatment that make them respond differently to the same treatment. We hope that this study will enable us to develop a method to identify women who are suitable for this form of treatment. We also want to understand why some cancer cells don't get killed with paclitaxel. This information will help us to select treatment to suit an individual patient, and thus improve the outcome of treatment and avoid giving treatment that will not benefit the patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female ≥ 18 years of age
* Newly diagnosed and histology confirmed primary high grade serous ovarian cancer, high grade serous fallopian tube cancer and primary peritoneal carcinoma.
* Radiological and laparoscopic confirmation of FIGO stage 3C or 4 ovarian cancer.
* Radiological evidence of omental or peritoneal deposits that are accessible for radiology-guided biopsy.
* At least one lesion on CT scan measuring at least 2 cm in maximum diameter performed in the past 31 days. Slightly older scans may be accepted at the discretion of the CI providing the results are considered to remain clinically relevant.
* Eastern Cooperative Oncology Group (ECOG) performance score of 0-2
* Life expectancy of at least 6 months.
* The patient is willing and able to provide written informed consent and comply with the protocol for the duration of the study, and scheduled visits and examinations.
* Acceptable haematological and biochemical indices